# The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

> **NCT06921486** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.** · enrollment: 1003 (actual)

## Conditions studied

- Obesity and Overweight

## Interventions

- **DRUG:** Phase IIb：Efsubaglutide Alfa 5 mg QW
- **DRUG:** Phase IIb：Efsubaglutide Alfa 10 mg QW
- **DRUG:** Phase IIb：Efsubaglutide Alfa 20 mg QW
- **DRUG:** Phase IIb：Efsubaglutide Alfa 20 mg Q2W
- **DRUG:** Phase IIb：Placebo
- **DRUG:** Phase III：Recommended Phase 3 Dose High Dose
- **DRUG:** Phase III：Recommended Phase 3 Dose Low Dose
- **DRUG:** Phase III：Placebo

## Key facts

- **NCT ID:** NCT06921486
- **Lead sponsor:** Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1003 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06921486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06921486, "The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06921486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*